Impact of treatment delay in acute myeloid leukemia revisited.
作者信息
Juliusson Gunnar, Hagberg Oskar, Lazarevic Vladimir Lj, Lehmann Sören, Höglund Martin
机构信息
Department of Hematology, Skåne University Hospital, Lund, Sweden.
Department of Hematology.
出版信息
Blood Adv. 2021 Feb 9;5(3):787-790. doi: 10.1182/bloodadvances.2020003806.
Abstract
摘要
相似文献
1
Impact of treatment delay in acute myeloid leukemia revisited.急性髓系白血病治疗延迟的影响再探讨。
Blood Adv. 2021 Feb 9;5(3):787-790. doi: 10.1182/bloodadvances.2020003806.
2
Patient-Centered Insights on Treatment Decision Making and Living with Acute Myeloid Leukemia and Other Hematologic Cancers.患者对急性髓系白血病和其他血液系统癌症的治疗决策和生活的看法。
Patient. 2020 Feb;13(1):83-102. doi: 10.1007/s40271-019-00384-9.
3
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.从诊断到开始强化化疗的时间不会对急性髓系白血病患者的预后产生不利影响。
Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30.
4
Interferon-α in acute myeloid leukemia: an old drug revisited.干扰素-α 在急性髓系白血病中的应用：一种被重新审视的老药。
Leukemia. 2011 May;25(5):739-48. doi: 10.1038/leu.2010.324. Epub 2011 Jan 28.
5
[Advances in the genetic abnormalities involved in the pathogenesis of acute myeloid leukemia].[急性髓系白血病发病机制中涉及的基因异常研究进展]
Rev Fac Cien Med Univ Nac Cordoba. 2019 Jun 19;76(2):77-78. doi: 10.31053/1853.0605.v76.n2.24329.
6
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.吉瑞替尼：一种用于治疗复发或难治性急性髓系白血病患者的类FMS样酪氨酸激酶3/AXL酪氨酸激酶抑制剂。
J Oncol Pharm Pract. 2020 Jul;26(5):1200-1212. doi: 10.1177/1078155220918006. Epub 2020 Apr 26.
7
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.急性髓系白血病中对去甲基化药物治疗反应的突变相关性
Haematologica. 2016 Nov;101(11):e457-e460. doi: 10.3324/haematol.2016.148999. Epub 2016 Jul 14.
8
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.瑞巴替尼（DCC-2036）用于复发慢性髓性白血病和急性髓性白血病患者的1期剂量探索研究。
Haematologica. 2017 Mar;102(3):519-528. doi: 10.3324/haematol.2016.152710. Epub 2016 Dec 7.
9
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?急性髓系白血病的维持治疗再探讨：新药物会重燃旧有兴趣吗？
Curr Opin Hematol. 2010 Mar;17(2):85-90. doi: 10.1097/MOH.0b013e3283366bf4.
10
Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Clinical Practice?下一代测序与急性髓系白血病微小残留病的检测：准备好应用于临床实践了吗？
JAMA. 2015 Aug 25;314(8):778-80. doi: 10.1001/jama.2015.9452.
引用本文的文献
1
Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.急性髓系白血病患者接受强化化疗时治疗开始时间对缓解质量的影响。
Cancers (Basel). 2025 Jun 18;17(12):2028. doi: 10.3390/cancers17122028.
2
Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges.确保患者能够获得针对罕见病的基因疗法：应对报销和保险覆盖方面的挑战。
Mol Ther Methods Clin Dev. 2025 Jan 17;33(1):101403. doi: 10.1016/j.omtm.2024.101403. eCollection 2025 Mar 13.
3
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.对于采用基于维奈克拉的方案治疗的新诊断急性髓系白血病患者，从诊断到治疗的时间对生存无影响。
Haematologica. 2024 Aug 1;109(8):2469-2477. doi: 10.3324/haematol.2024.285225.
4
Transforming Acute Myeloid Leukemia Treatment Through Next-Generation Sequencing: A Single-Center Experience.通过下一代测序改变急性髓系白血病治疗：单中心经验
Cureus. 2023 Sep 25;15(9):e45917. doi: 10.7759/cureus.45917. eCollection 2023 Sep.
5
Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions.医疗补助计划对获批基因和细胞疗法的覆盖实践：现存障碍与政策解决方案建议
Mol Ther Methods Clin Dev. 2023 May 16;29:513-521. doi: 10.1016/j.omtm.2023.05.015. eCollection 2023 Jun 8.
6
Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology.急性髓系白血病的治疗：肿瘤学全科医生的综述。
Curr Oncol. 2022 Aug 30;29(9):6245-6259. doi: 10.3390/curroncol29090491.
7
Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.从诊断到治疗的时间与急性髓系白血病患者的生存相关：来自国家癌症数据库的 55985 例患者分析。
Br J Haematol. 2022 Oct;199(2):256-259. doi: 10.1111/bjh.18381. Epub 2022 Jul 28.
8
New Therapeutic Strategies for Adult Acute Myeloid Leukemia.成人急性髓系白血病的新治疗策略
Cancers (Basel). 2022 Jun 5;14(11):2806. doi: 10.3390/cancers14112806.
9
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.老年急性髓系白血病患者应接受个体化治疗。
Curr Oncol Rep. 2022 Nov;24(11):1387-1400. doi: 10.1007/s11912-022-01299-9. Epub 2022 Jun 2.
10
Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India.真实世界中急性髓细胞白血病管理面临的挑战：来自印度北部某单一中心的经验。
Ann Hematol. 2022 Jun;101(6):1261-1273. doi: 10.1007/s00277-022-04814-x. Epub 2022 Mar 24.
本文引用的文献
1
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?从诊断到治疗的时间是否会影响新诊断为急性髓系白血病患者的预后？
Blood. 2020 Aug 13;136(7):823-830. doi: 10.1182/blood.2019004583.
2
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting.在基于人群的背景下，FLT3-ITD 和 NPM1 突变对成人 AML 的预后影响与年龄相关。
Blood Adv. 2020 Mar 24;4(6):1094-1101. doi: 10.1182/bloodadvances.2019001335.
3
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.50至75岁急性髓系白血病男性患者在20年期间生存率提高。
Blood. 2019 Oct 31;134(18):1558-1561. doi: 10.1182/blood.2019001728.
4
Acute Myeloid Leukemia.急性髓系白血病
N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184.
5
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.从诊断到开始强化化疗的时间不会对急性髓系白血病患者的预后产生不利影响。
Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30.
6
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.年龄与急性髓系白血病：来自瑞典急性白血病登记处关于治疗决策和结局的真实世界数据。
Blood. 2009 Apr 30;113(18):4179-87. doi: 10.1182/blood-2008-07-172007. Epub 2008 Nov 13.
7
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.从诊断到开始治疗的时间可预测年轻急性髓系白血病患者的生存率，但对老年患者则不然。
Blood. 2009 Jan 1;113(1):28-36. doi: 10.1182/blood-2008-05-157065. Epub 2008 Sep 30.
Zotero 插件